Browsing Category
Pharma Industry News
4743 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Doctor’s Best launches women’s multi-vitamin with 21 essential nutrients
Doctor’s Best unveils a women’s multi-vitamin with 21 essential nutrients, blending science, sustainability, and women-focused wellness in one formula.
FDA clears Mabwell’s next-gen ADC 7MW4911: What’s at stake in the global GI oncology race?
Mabwell secures FDA IND for CDH17-targeting ADC 7MW4911, marking a major step in GI cancer therapy. Find out how this could reshape advanced oncology care.
Can Pfizer’s pipeline offset looming patent cliffs despite a stronger 2025 forecast?
Can Pfizer’s oncology and rare disease pipeline replace billions lost to patent cliffs? Explore how the drugmaker compares with Merck, Bristol Myers, and AstraZeneca.
Glenmark’s AbbVie deal: Can ISB 2001 make it India’s first true global biologics play?
Glenmark’s AbbVie deal for trispecific antibody ISB 2001 could redefine India’s role in global biologics—find out why this partnership matters now.
WuXi Biologics wins EMA approval in Ireland as WuXiUP automation signals new chapter in global biologics manufacturing
WuXi Biologics secures EMA approval in Ireland and achieves WuXiUP automated continuous production, reinforcing global dual sourcing and biomanufacturing innovation.
Skyhawk Therapeutics and Merck sign $2bn RNA drug discovery pact targeting neurological disorders
Skyhawk Therapeutics inks $2B Merck deal to develop RNA-targeted neurology drugs, highlighting splicing modulation as a new frontier.
Glenmark Pharmaceuticals balances modest Q1 FY26 growth with innovation drive, global partnerships and robust pipeline ambitions
Glenmark’s Q1 FY26 results reveal modest growth but highlight strong specialty launches, AbbVie licensing deal, and a robust innovation pipeline.
vTv Therapeutics begins Phase 3 CATT1 trial of cadisegliatin in type 1 diabetes patients
vTv Therapeutics has launched its Phase 3 CATT1 trial of cadisegliatin in type 1 diabetes. Find out what this means for patients and investors today.
OS Therapies reports strong survival benefit in Phase 2b osteosarcoma trial, eyes FDA accelerated approval
OS Therapies’ OST-HER2 trial shows 66.6% two-year survival in recurrent pulmonary osteosarcoma. Find out what this could mean for FDA approval.
Children’s Hospital of Philadelphia study uncovers missing RNA fragments as potential key to targeted immunotherapy for pediatric brain tumors
CHOP researchers discover that missing RNA microexons in pediatric brain tumors create a targetable NRCAM variant, opening new paths for safer immunotherapy.